Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Characterization of Natural Killer Cells in Severe Asthma Patients
NCT06015256Recruiting
- Sponsor
- Inserm
- Start
- Sep 2023
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Trial (4 arms), sponsored by Inserm. Primary endpoint: Changes in expression of one or more molecules on the surface of NK cells. Started Sep 2023; status: recruiting.
Beyond the preview
Go deeper on NCT06015256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015256.